Company intelligence / Profile preview
Holostem
- Ownership
- Private
- Development stage
- Commercial
Overview
Holostem pioneered the development, manufacture, registration, and distribution of advanced therapies based on cultures of epithelial stem cells. Its flagship products include Europe’s first approved autologous limbal stem cell therapy to restore vision after ocular burns and advanced treatments for epidermolysis bullosa. The company has transitioned into a nonprofit foundation under the ownership of Fondazione Enea Tech e Biomedical as of December 2023 but continues its mission in translational medicine with an international reputation.
- Therapeutic areas
- Rare DiseasesDermatologyOphthalmology
- Modalities
- Cell therapyGene therapyEpithelial stem cell-based therapies
- Industry
- Biotech
Drug pipeline
7 assets6 more assets in the full pipeline.
Partnerships
Beyond the preview
Go deeper on Holostem.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Holostem.